Reimagining Medicine

Company overview Financial review 2023 priorities Appendix Expected currency impact for 2023 Currency impact vs. PY %pts, assuming late-January exchange rates prevail in 2023 FX impact on net sales I I 0 to +1 FX impact on core operating income I I I -3 to -4 -7 -6 -9 -8 I Q4 FY Q1 FY Q4 FY 2022 2023 2022 I I I Actual Simulation 45 Investor Relations | Q4 2022 Results FINANCIAL PROFILE -5 -1 Q1 FY 2023 NOVARTIS | Reimagining Medicine

View entire presentation